ProMIS Neurosciences awards Ivana Rubino 80,000 options

Continued service through each vesting date is a condition of the award’s monthly vesting schedule.

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. (PMN) reported that Chief Commercial Officer Ivana Rubino received an award of options covering 80,000 common shares on October 5, 2026. The options have an exercise price of $9.37 per share and expire on October 5, 2036. Twenty-five percent vests on October 5, 2026; the remaining shares vest monthly over the following three years, subject to continued service through each vesting date.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 1 txn

Insider Rubino Ivana

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy) F1	80,000	$0.00	$0.00

Holdings After Transaction: Option (right to buy) — 80,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date.

Key Figures

Underlying common shares: 80,000 shares Exercise price: $9.37 per share Initial vesting: 25% +2 more

5 metrics

Underlying common shares 80,000 shares Options awarded October 5, 2026

Exercise price $9.37 per share Option award

Initial vesting 25% Vests October 5, 2026

Remaining vesting period Three years Remaining shares vest monthly, subject to continued service

Expiration date October 5, 2036 Option award

Key Terms

Option (right to buy), exercise price, vest

3 terms

Option (right to buy) financial

"Option (right to buy)"

exercise price financial

"exercise price of $9.37"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"shares subject to this option shall vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option award did PMN Chief Commercial Officer Ivana Rubino receive?

Ivana Rubino received an award of options covering 80,000 common shares on October 5, 2026. The options have an exercise price of $9.37 per share and expire on October 5, 2036.

When do Ivana Rubino’s PMN options vest?

Twenty-five percent of the shares subject to the option vest on October 5, 2026, with the remaining shares vesting monthly over the following three years. Vesting is subject to continued service to the issuer through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 05:05 PM Accepted by SEC EDGAR 10/06/2026 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubino Ivana

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$9.37	10/05/2026		A		80,000		(1)	10/05/2036	Common Shares	80,000	$0	80,000	D

Explanation of Responses:

1. 25% of the shares subject to this option shall vest on October 5, 2026, with the remaining shares vesting monthly over the three (3) years thereafter, subject to continued service to the Issuer through each vesting date.

	/s/ Max A. Milbury, Attorney-in-Fact	10/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)